

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 66

October 14, 2024

ISSUE No.  
**1713**

### IN THIS ISSUE

A New RSV Vaccine (*mResvia*) for Adults  $\geq 60$  Years Old .....p 166

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter®

## on Drugs and Therapeutics

Volume 66 (Issue 1713)

October 14, 2024

[Take CME Exams](#)

### ▶ A New RSV Vaccine (*mResvia*) for Adults ≥60 Years Old

The FDA has licensed *mResvia* (Moderna), an mRNA respiratory syncytial virus (RSV) vaccine, for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old. It is the first mRNA vaccine to be licensed in the US for this indication. Two recombinant RSV vaccines, *Arexvy* and *Abrysvo*, are also available for prevention of RSV LRTD.<sup>1</sup> *Arexvy* is approved for use in adults ≥50 years old.<sup>2</sup> *Abrysvo* is approved for use in adults ≥60 years old and in pregnant women to prevent RSV LRTD in their infants.

#### Pronunciation and Abbreviation Key

*mResvia*: em res vee uh  
RSV = respiratory syncytial virus  
LRTD = lower respiratory tract disease

**RSV DISEASE** – RSV typically causes a mild upper respiratory tract infection in adults, but older adults, particularly those with underlying health conditions, have an increased risk of RSV-associated hospitalization. RSV epidemics in the Northern Hemisphere typically occur between October and April, peaking in December or January.

**EFFICACY OF RECOMBINANT VACCINES** – Both *Arexvy* and *Abrysvo* have been shown to reduce the incidence of RSV LRTD in adults ≥60 years old.<sup>1</sup> A case-control analysis of patients ≥60 years old hospitalized for acute respiratory illness found that vaccination with a recombinant RSV vaccine was about 75% effective against RSV-associated hospitalization during the first season of use.<sup>3</sup> Use of *Abrysvo* in pregnant women reduced the incidence of medically-attended RSV LRTD in their infants during one RSV season.<sup>1</sup>

**THE NEW VACCINE** – *mResvia* is a lipid nanoparticle-encapsulated, mRNA-based vaccine. It encodes a stabilized prefusion form of the RSV fusion (F) glycoprotein derived from an RSV A strain. The RSV prefusion F glycoprotein mediates viral fusion and host-cell entry and elicits neutralizing antibodies.

#### Key Points: *mResvia*

- ▶ **Description:** An mRNA respiratory syncytial virus (RSV) vaccine encoding a stabilized prefusion form of the RSV fusion (F) glycoprotein.
- ▶ **Indication:** FDA-approved for prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ≥60 years old.
- ▶ **Efficacy:** A single dose has prevented RSV LRTD in adults ≥60 years old compared to placebo. One dose of *mResvia* appears to be less effective over two RSV seasons than one dose of a recombinant RSV vaccine (*Arexvy* or *Abrysvo*).
- ▶ **Adverse Effects:** Most common are injection-site pain, axillary swelling or tenderness, fatigue, headache, myalgia, arthralgia, and chills.
- ▶ **Dosage:** A single 50 mcg/0.5 mL IM dose.
- ▶ **Cost:** The wholesale acquisition cost for one dose is \$290.
- ▶ **Conclusion:** The CDC Advisory Committee on Immunization Practices (ACIP) recommends a single dose of any available RSV vaccine for all adults ≥75 years old and for those 60-74 years old at increased risk of severe RSV disease.

The same antigen is used in *Arexvy* and *Abrysvo*.

**CLINICAL STUDIES** – FDA approval of *mResvia* was based on the preliminary results of an ongoing observer-blinded trial (ConquerRSV) in 35,064 adults ≥60 years old who were randomized to receive a single dose of *mResvia* or placebo. The vaccine was effective, compared to placebo, in preventing a first episode of RSV LRTD (see Table 2). Vaccine efficacy against RSV-associated acute respiratory disease was 68.4%; efficacy against RSV A was higher than that against RSV B (78.5% vs 51.7%).<sup>4</sup>

A follow-up report found that a single dose of *mResvia* was ~50% effective in preventing RSV LRTD over 18 months in adults ≥60 years old.<sup>5</sup> Higher efficacy rates against RSV LRTD over two RSV seasons have been reported following a single dose of *Arexvy* or *Abrysvo* (67.7% over 23.3 months with *Arexvy* and 81.5% over 16.4 months with *Abrysvo*).<sup>6,7</sup>

Table 1. RSV Vaccines

Vaccine	Dose/Schedule	Cost <sup>1</sup>
<i>Arexvy</i> (GSK)	120 mcg/0.5 mL IM once	\$294.00
<i>Abrysvo</i> (Pfizer)	120 mcg/0.5 mL IM once	295.00
<i>mResvia</i> (Moderna)	50 mcg/0.5 mL IM once	290.00

1. Approximate WAC for one dose. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. September 5, 2024. Reprinted with permission by First Databank, Inc. All rights reserved. ©2024. [www.fdbhealth.com/policies/drug-pricing-policy](http://www.fdbhealth.com/policies/drug-pricing-policy).

**Table 2. Efficacy of *mResvia* in Adults  $\geq 60$  Years Old<sup>1</sup>**

	RSV LRTD ( $\geq 2$ signs/symptoms) <sup>2</sup>	RSV LRTD ( $\geq 3$ signs/symptoms) <sup>2</sup>
Median follow-up 3.7 months	78.7%	80.9%
Median follow-up 8.6 months	62.5%	61.1%

RSV LRTD = respiratory syncytial virus-associated lower respiratory tract disease

1. E Wilson et al. N Engl J Med 2023; 389:2233; R Das. ACIP presentation slides: June 26-28, 2024 meeting.
2. Vaccine efficacy (based on hazard ratio, *mResvia* vs placebo) for prevention of a first episode of RSV LRTD with  $\geq 2$  lower respiratory signs/symptoms or  $\geq 3$  lower respiratory signs/symptoms starting 14 days after vaccination.

**ADVERSE EFFECTS** – In the ConquerRSV trial, the most common local adverse effects reported within 7 days of *mResvia* vaccination were injection-site pain (55.9%) and axillary swelling or tenderness (15.2%). Systemic adverse effects included fatigue (30.8%), headache (26.7%), myalgia (25.6%), arthralgia (21.7%), and chills (11.6%). More cases of urticaria were reported with *mResvia* than with placebo within 28 days after administration (15 vs 5). One participant in the *mResvia* group developed facial paralysis 4 days after vaccination. Atrial fibrillation and Guillain-Barré syndrome (GBS) were reported following administration of *Arexvy* or *Abrysvo* in clinical trials. Vaccine-related cardiac arrhythmias and GBS were not reported in clinical trials with *mResvia*.<sup>5</sup>

**ACIP RECOMMENDATIONS** – The CDC Advisory Committee on Immunization Practices (ACIP) has updated its recommendations for use of RSV vaccines in older adults. A single dose of an RSV vaccine is now recommended for all adults  $\geq 75$  years old and for those 60-74 years old at increased risk of severe RSV disease (see Table 3).<sup>8</sup> For optimal protection, the vaccine should be given before the onset of the RSV season. Administration of an RSV vaccine and other adult vaccines during the same visit is considered acceptable, but local or systemic reactogenicity could increase.<sup>9</sup>

**DOSAGE AND ADMINISTRATION** – The *mResvia* vaccine is supplied as a frozen suspension in prefilled syringes containing a single 50 mcg/0.5 mL IM dose. The syringe can be thawed in the refrigerator for 60

**Table 3. Risk Factors for Severe RSV Disease**

- ▶ Chronic medical conditions (e.g., pulmonary, cardiac, renal)
- ▶ Moderate or severe immune compromise
- ▶ Frailty
- ▶ Severe obesity (body mass index  $>40$  kg/m<sup>2</sup>)
- ▶ Residence in a nursing home or other long-term care facility

minutes and should stand at room temperature for 10-20 minutes before administration. A syringe that is thawed at room temperature is ready to be administered after 45 minutes.

**CONCLUSION** – A single dose of *mResvia*, the first mRNA respiratory syncytial virus (RSV) vaccine, was effective in preventing RSV-associated lower respiratory tract disease during one RSV season in adults  $\geq 60$  years old. Follow-up data suggest that one dose of *mResvia* may offer less protection over two RSV seasons than one dose of *Arexvy* or *Abrysvo*, the recombinant RSV vaccines available in the US. The CDC Advisory Committee on Immunization Practices recommends a single dose of any available RSV vaccine for all adults  $\geq 75$  years old and for those 60-74 years old at increased risk of severe RSV disease. ■

1. Two vaccines (*Arexvy* and *Abrysvo*) for prevention of RSV disease. Med Lett Drugs Ther 2023; 65:155.
2. In brief: RSV vaccine (*Arexvy*) for ages 50-59. Med Lett Drugs Ther 2024; 66:113.
3. D Surie et al. RSV vaccine effectiveness against hospitalization among US adults 60 years and older. JAMA 2024 Sep 4 (epub).
4. E Wilson et al. Efficacy and safety of an mRNA-based RSV preF vaccine in older adults. N Engl J Med 2023; 389:2233.
5. R Das. Update on Moderna's RSV vaccine, *mResvia* (mRNA-1345), in adults  $\geq 60$  years of age. ACIP presentation slides: June 26-28, 2024 meeting. Available at: <https://bit.ly/4ci07hH>. Accessed September 26, 2024.
6. I Munjal. RSVpreF adult clinical development update. ACIP presentation slides: June 26-28, 2024 meeting. Available at: <https://bit.ly/4ci07hH>. Accessed September 26, 2024.
7. S Gerber. *Arexvy* (adjuvanted RSVpreF3) 2-year update. ACIP presentation slides: June 26-28, 2024 meeting. Available at: <https://bit.ly/4ci07hH>. Accessed September 26, 2024.
8. A Britton et al. Use of respiratory syncytial virus vaccines in adults aged  $\geq 60$  years: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morb Mortal Wkly Rep 2024; 73:696.
9. CDC. Vaccines and immunizations. Healthcare providers: RSV vaccination for adults 60 years of age and over. July 3, 2024. Available at: <https://bit.ly/3yCOA1n>. Accessed September 26, 2024.

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

#### Address:

The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
www.medicalletter.org

#### Customer Service:

Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: [custserv@medicalletter.org](mailto:custserv@medicalletter.org)

#### Permissions:

To reproduce any portion of this issue,  
please e-mail your request to:  
[permissions@medicalletter.org](mailto:permissions@medicalletter.org)

#### Subscriptions (US):

1 year - \$159; \$65 per year  
for students, interns, residents,  
and fellows in the US and Canada.  
Reprints - \$45 per issue or article

#### Site License Inquiries:

E-mail: [SubQuote@medicalletter.org](mailto:SubQuote@medicalletter.org)  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.

Get Connected: 

Copyright 2024. ISSN 1523-2859

